Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
NCT ID NCT07765966
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This early-stage trial is testing an experimental therapy called RXIM002 in adults with relapsed or refractory autoimmune cytopenias, including immune thrombocytopenia (ITP). The therapy uses a special RNA molecule to instruct the body to produce CAR T cells that target and potentially calm the immune cells attacking blood cells. The study aims to evaluate the safety, tolerability, and preliminary effectiveness of this approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RXIM002, an experimental RNA-based therapy that instructs the body to make CAR T cells targeting CD19
- What this could lead to
- If successful, this could lead to a new treatment option for people with autoimmune cytopenias that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. There are risks of side effects, and the therapy may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bispecific antibody tame two autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Will a new drug form work the same? study tests two versions of SKI-O-703
- New drug mimics IVIg to fight low platelet disorder
- New drug combo aims to tame stubborn blood disorders
- New drug RAY121 tested for Long-Term control of autoimmune diseases